ReviewNanomaterials (Basel, Switzerland)2020
The Rational Design and Biological Mechanisms of Nanoradiosensitizers.
Review in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Nanoparticle radiosensitizers in cancer radiotherapy: bridging preclinical promise and clinical reality.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- RNA methylation-related inhibitors: Biological basis and therapeutic potential for cancer therapy.Clinical and translational medicine · 2024Review
- Sarcoma cell-specific radiation sensitization by titanate scrolled nanosheets: insights from physicochemical analysis and transcriptomic profiling.Scientific reports · 2024Article
- Advancements in pseudouridine modifying enzyme and cancer.Frontiers in cell and developmental biology · 2024Review
- New Frontiers in Colorectal Cancer Treatment Combining Nanotechnology with Photo- and Radiotherapy.Cancers · 2023Review
- Advances in the Mechanistic Understanding of Iron Oxide Nanoparticles' Radiosensitizing Properties.Nanomaterials (Basel, Switzerland) · 2023Article
- Recent progress in cancer cell membrane-based nanoparticles for biomedical applications.Beilstein journal of nanotechnology · 2023Review
- Design Principles of Hybrid Nanomaterials for Radiotherapy Enhanced by Photodynamic Therapy.International journal of molecular sciences · 2022Review
- Radiation nanosensitizers in cancer therapy-From preclinical discoveries to the outcomes of early clinical trials.Bioengineering & translational medicine · 2022Review
- Requirements for Designing an Effective Metallic Nanoparticle (NP)-Boosted Radiation Therapy (RT).Cancers · 2021Review
- Impact of the Spectral Composition of Kilovoltage X-rays on High-Z Nanoparticle-Assisted Dose Enhancement.International journal of molecular sciences · 2021Article
- Application of Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Radiotherapy (RT) has been widely used for cancer treatment. However, the intrinsic drawbacks of RT, such as radiotoxicity in normal tissues and tumor radioresistance, promoted the development of radiosensitizers. To date, various kinds of nanoparticles have been found to act as radiosensitizers in cancer radiotherapy. This review focuses on the current state of nanoradiosensitizers, especially the related biological mechanisms, and the key design strategies for generating nanoradiosensitizers. The regulation of oxidative stress, DNA damage, the cell cycle, autophagy and apoptosis by nanoradiosensitizers in vitro and in vivo is highlighted, which may guide the rational design of therapeutics for tumor radiosensitization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.